General Information of Drug (ID: DMT4I2W)

Drug Name
Aom-0890 Drug Info
Synonyms Aom-0891; PDE5 inhibitors (oral/tablet, erectile dysfunction); PDE5 inhibitors (oral/tablet, erectile dysfunction), Hangzhou Adamerck
Indication
Disease Entry ICD 11 Status REF
Erectile dysfunction HA01.1 Investigative [1]
Cross-matching ID
TTD Drug ID
DMT4I2W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tadalafil DMJZHT1 Benign prostatic hyperplasia GA90 Approved [2]
Udenafil DM1IQRP Erectile dysfunction HA01.1 Approved [3]
Vardenafil DMTBGW8 Cystic fibrosis CA25 Approved [4]
Dipyridamole DMXY30O Atrial fibrillation BC81.3 Approved [5]
Papaverine DMCA9QP Brain ischaemia 8B1Z Approved [6]
Avanafil DM75CXN Erectile dysfunction HA01.1 Approved [7]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [8]
ICARIIN DMOJQGT N. A. N. A. Phase 3 [9]
EXISULIND DMBY56U Colorectal cancer 2B91.Z Phase 3 [10]
PF-489791 DM3C8GQ Chronic obstructive pulmonary disease CA22 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304).
2 Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
3 Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
4 The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
5 Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
6 Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
9 Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
10 Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
11 Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.